Most of the patients had IgG myeloma (10/17, 58.8%), the others had IgA (5/17, 29.4%), IgD (1/17, 5.9%) and λ light chain (1/17, 5.9%) myeloma. This evidence concerns the gene CD79A and plasma cell myeloma.